Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGY825 in Advanced Non-small Cell Lung Cancer
NCT05275868Phase 1Terminated
- Sponsor
- Novartis
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of MGY825 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of adverse events and serious adverse events at 28 months, Frequency of dose interruptions and reductions at 28 months and 2 more. Started Oct 2022; status: terminated.
02
Drugs
MGY825
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05275868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275868.